122 related articles for article (PubMed ID: 33915257)
1. Design, synthesis and antitumor activity of phthalazine-1,4-dione-based menaquinone analogs.
Fujii S; Miura T; Oikawa T; Qin XY; Kojima S; Kagechika H
Bioorg Med Chem Lett; 2021 Jul; 43():128065. PubMed ID: 33915257
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives.
Xue DQ; Zhang XY; Wang CJ; Ma LY; Zhu N; He P; Shao KP; Chen PJ; Gu YF; Zhang XS; Wang CF; Ji CH; Zhang QR; Liu HM
Eur J Med Chem; 2014 Oct; 85():235-44. PubMed ID: 25086915
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition.
Elmeligie S; Aboul-Magd AM; Lasheen DS; Ibrahim TM; Abdelghany TM; Khojah SM; Abouzid KAM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1347-1367. PubMed ID: 31322015
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, molecular modelling and anticancer evaluation of new pyrrolo[1,2-b]pyridazine and pyrrolo[2,1-a]phthalazine derivatives.
Popovici L; Amarandi RM; Mangalagiu II; Mangalagiu V; Danac R
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):230-243. PubMed ID: 30734610
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of new phthalazine-based derivatives as potential EGFR inhibitors for the treatment of hepatocellular carcinoma.
Boraei ATA; Ashour HK; El Tamany ESH; Abdelmoaty N; El-Falouji AI; Gomaa MS
Bioorg Chem; 2019 Apr; 85():293-307. PubMed ID: 30654221
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives.
Zhang S; Zhao Y; Liu Y; Chen D; Lan W; Zhao Q; Dong C; Xia L; Gong P
Eur J Med Chem; 2010 Aug; 45(8):3504-10. PubMed ID: 20537434
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
Lu X; Peng Y; Wang C; Yang J; Bao X; Dong Q; Zhao W; Tan W; Dong X
Eur J Med Chem; 2017 Sep; 138():384-395. PubMed ID: 28688278
[TBL] [Abstract][Full Text] [Related]
9. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.
Eldehna WM; Abou-Seri SM; El Kerdawy AM; Ayyad RR; Hamdy AM; Ghabbour HA; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 May; 113():50-62. PubMed ID: 26922228
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones.
Eldehna WM; Ibrahim HS; Abdel-Aziz HA; Farrag NN; Youssef MM
Eur J Med Chem; 2015 Jan; 89():549-60. PubMed ID: 25462265
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
[TBL] [Abstract][Full Text] [Related]
12. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anticancer activities of novel 1,4-disubstituted phthalazines.
Li J; Zhao YF; Yuan XY; Xu JX; Gong P
Molecules; 2006 Jul; 11(7):574-82. PubMed ID: 17971729
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives.
Liu Y; Zhang S; Li Y; Wang J; Song Y; Gong P
Arch Pharm (Weinheim); 2012 Apr; 345(4):287-93. PubMed ID: 22006840
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
Liu Z; Wang R; Guo R; Hu J; Li R; Zhao Y; Gong P
Bioorg Med Chem; 2014 Jul; 22(14):3642-53. PubMed ID: 24882675
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
[TBL] [Abstract][Full Text] [Related]
17. Mono- and bis-pyrazolophthalazines: Design, synthesis, cytotoxic activity, DNA/HSA binding and molecular docking studies.
Hamidinasab M; Ameri A; Hekmat A; Forootanfar H; Mortezazadeh T; Bodaghifard MA; Peytam F; Esmaeili R; Foroumadi A; Sharifzadeh M; Mobinikhaledi A; Khoobi M
Bioorg Med Chem; 2021 Jan; 30():115944. PubMed ID: 33352388
[TBL] [Abstract][Full Text] [Related]
18. 3-[(6-Arylamino)pyridazinylamino]benzoic acids: design, synthesis and in vitro evaluation of anticancer activity.
Abouzid KA; Khalil NA; Ahmed EM; Mohamed KO
Arch Pharm Res; 2013 Jan; 36(1):41-50. PubMed ID: 23307426
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel 5,6-disubstituted pyridine-2,3-dione-3-thiosemicarbazone derivatives as potential anticancer agents.
Xie W; Xie S; Zhou Y; Tang X; Liu J; Yang W; Qiu M
Eur J Med Chem; 2014 Jun; 81():22-7. PubMed ID: 24819956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
